Rationale and design of the Cancer Immunotherapy Evidence Living (CIEL) Library: A continuously updated clinical trial database of cancer immunotherapies
K Boesen, J Hirt, P Düblin, H Läubli, B Kassenda, LG Hemkens, P Janiaud
doi: https://doi.org/10.1101/2024.04.26.24306436
K Boesen
1Research Center for Clinical Neuroimmunology and Neuroscience (RC2NB), University Hospital Basel and University of Basel, Switzerland
J Hirt
1Research Center for Clinical Neuroimmunology and Neuroscience (RC2NB), University Hospital Basel and University of Basel, Switzerland
2Department of Health, Eastern Switzerland University of Applied Sciences, Rosenbergstrasse 59, 9000 St. Gallen, Switzerland
P Düblin
3Department of Clinical Research, University Hospital Basel and University of Basel, Basel, Switzerland
H Läubli
4Department of Medical Oncology, University Hospital and University of Basel, Basel, Switzerland
B Kassenda
4Department of Medical Oncology, University Hospital and University of Basel, Basel, Switzerland
LG Hemkens
1Research Center for Clinical Neuroimmunology and Neuroscience (RC2NB), University Hospital Basel and University of Basel, Switzerland
3Department of Clinical Research, University Hospital Basel and University of Basel, Basel, Switzerland
5Meta-Research Innovation Center at Stanford (METRICS), Stanford University, Stanford, California, USA
P Janiaud
1Research Center for Clinical Neuroimmunology and Neuroscience (RC2NB), University Hospital Basel and University of Basel, Switzerland
Data Availability
All data produced in the present study are available upon reasonable request to the authors
Posted April 27, 2024.
Rationale and design of the Cancer Immunotherapy Evidence Living (CIEL) Library: A continuously updated clinical trial database of cancer immunotherapies
K Boesen, J Hirt, P Düblin, H Läubli, B Kassenda, LG Hemkens, P Janiaud
medRxiv 2024.04.26.24306436; doi: https://doi.org/10.1101/2024.04.26.24306436
Rationale and design of the Cancer Immunotherapy Evidence Living (CIEL) Library: A continuously updated clinical trial database of cancer immunotherapies
K Boesen, J Hirt, P Düblin, H Läubli, B Kassenda, LG Hemkens, P Janiaud
medRxiv 2024.04.26.24306436; doi: https://doi.org/10.1101/2024.04.26.24306436
Subject Area
Subject Areas
- Addiction Medicine (325)
- Allergy and Immunology (635)
- Anesthesia (168)
- Cardiovascular Medicine (2417)
- Dermatology (208)
- Emergency Medicine (382)
- Epidemiology (11829)
- Forensic Medicine (10)
- Gastroenterology (705)
- Genetic and Genomic Medicine (3792)
- Geriatric Medicine (353)
- Health Economics (641)
- Health Informatics (2424)
- Health Policy (943)
- Hematology (344)
- HIV/AIDS (794)
- Medical Education (372)
- Medical Ethics (105)
- Nephrology (404)
- Neurology (3547)
- Nursing (200)
- Nutrition (531)
- Oncology (1844)
- Ophthalmology (541)
- Orthopedics (223)
- Otolaryngology (287)
- Pain Medicine (234)
- Palliative Medicine (68)
- Pathology (450)
- Pediatrics (1044)
- Primary Care Research (425)
- Public and Global Health (6212)
- Radiology and Imaging (1301)
- Respiratory Medicine (838)
- Rheumatology (381)
- Sports Medicine (327)
- Surgery (409)
- Toxicology (51)
- Transplantation (174)
- Urology (148)